用于系统性硬化症临床试验的改良罗德南皮肤评分的标准化。
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.
作者信息
Khanna Dinesh, Furst Daniel E, Clements Philip J, Allanore Yannick, Baron Murray, Czirjak Lazlo, Distler Oliver, Foeldvari Ivan, Kuwana Masataka, Matucci-Cerinic Marco, Mayes Maureen, Medsger Thomas, Merkel Peter A, Pope Janet E, Seibold James R, Steen Virginia, Stevens Wendy, Denton Christopher P
机构信息
University of Michigan Scleroderma Program, Ann Arbor, MI, USA.
UCLA, Los Angeles, CA, USA.
出版信息
J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.
Abstract
The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a primary or secondary outcome measure in clinical trials of systemic sclerosis (scleroderma). This state-of-art review provides a historical perspective of the development of the mRSS, summarizes the performance of mRSS as an outcome measure, provides guidance on assessing mRSS, and makes recommendations for incorporation of the mRSS into clinical trials.
摘要
改良罗德南皮肤评分（mRSS）是一种衡量皮肤厚度的指标，在系统性硬化症（硬皮病）的临床试验中用作主要或次要结局指标。本综述提供了mRSS发展的历史视角，总结了mRSS作为结局指标的表现，提供了评估mRSS的指导，并就将mRSS纳入临床试验提出了建议。
相似文献
1
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.
J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.
2
Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.
Int J Rheum Dis. 2019 Jun;22(6):1036-1040. doi: 10.1111/1756-185X.13523. Epub 2019 Mar 6.
3
Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Arthritis Res Ther. 2019 Jan 16;21(1):23. doi: 10.1186/s13075-019-1809-y.
4
Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score.
Rheumatology (Oxford). 2006 Jan;45(1):76-8. doi: 10.1093/rheumatology/kei106. Epub 2005 Sep 20.
5
High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
Rheumatol Int. 2018 Dec;38(12):2279-2288. doi: 10.1007/s00296-018-4156-4. Epub 2018 Sep 11.
6
Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis.
Int J Rheum Dis. 2019 Jan;22(1):96-102. doi: 10.1111/1756-185X.13433. Epub 2018 Nov 5.
7
Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.
J Scleroderma Relat Disord. 2020 Oct;5(3):167-171. doi: 10.1177/2397198320921044. Epub 2020 May 29.
8
9
Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study.
Arthritis Res Ther. 2019 May 28;21(1):129. doi: 10.1186/s13075-019-1919-6.
10
Skin model for improving the reliability of the modified Rodnan skin score for systemic sclerosis.
BMC Rheumatol. 2022 Jun 2;6(1):33. doi: 10.1186/s41927-022-00262-2.
引用本文的文献
1
Overlapping Connective Tissue Disease-Polymyositis and Diffuse Systemic Scleroderma: A Case Report.
Clin Med Insights Arthritis Musculoskelet Disord. 2025 Sep 2;18:11795441251370380. doi: 10.1177/11795441251370380. eCollection 2025.
2
Recombinant Human Annexin A5 Ameliorates Localized Scleroderma by Inhibiting the Activation of Fibroblasts and Macrophages.
Pharmaceutics. 2025 Jul 30;17(8):986. doi: 10.3390/pharmaceutics17080986.
3
Macrovascular Involvement in Systemic Sclerosis: Association Between Carotid Ultrasound Hemodynamics Parameters and Digital Ulcers.
Clin Pract. 2025 Aug 18;15(8):152. doi: 10.3390/clinpract15080152.
4
The serum levels of specific autoantibodies in systemic sclerosis predict a more severe skin involvement.
J Scleroderma Relat Disord. 2025 Jul 28:23971983251357991. doi: 10.1177/23971983251357991.
5
Performance of Ultra-High-Frequency Ultrasound in the Evaluation of Skin Involvement in Systemic Sclerosis: A Cross-Sectional Pilot Study.
Diagnostics (Basel). 2025 Jun 24;15(13):1600. doi: 10.3390/diagnostics15131600.
6
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025.
RMD Open. 2025 Jul 1;11(3):e005776. doi: 10.1136/rmdopen-2025-005776.
7
The correlation between retinal microvascular changes by optical coherence tomography angiography and nailfold capillaroscopic findings in patients with systemic sclerosis.
J Rheum Dis. 2025 Jul 1;32(3):198-210. doi: 10.4078/jrd.2024.0124. Epub 2025 Feb 19.
8
Efficacy of Mycophenolate Mofetil in Treating Skin Fibrosis in Systemic Sclerosis: A Systematic Review and Meta-Analysis.
J Clin Med. 2025 Jun 12;14(12):4187. doi: 10.3390/jcm14124187.
9
Examining the relationship between vascular biomarkers and both microangiopathy and cutaneous fibrosis in systemic sclerosis.
J Scleroderma Relat Disord. 2025 Jun 3:23971983251344040. doi: 10.1177/23971983251344040.
10
EPIDEMIOLOGICAL PROFILE OF PATIENTS WITH SYSTEMIC SCLEROSIS TREATED AT A QUATERNARY HOSPITAL IN THE STATE OF SÃO PAULO.
Acta Ortop Bras. 2025 Jun 2;33(2):e287081. doi: 10.1590/1413-785220253302e287081. eCollection 2025.
本文引用的文献
1
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5.
2
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.
Ann Rheum Dis. 2016 Oct;75(10):1743-8. doi: 10.1136/annrheumdis-2015-208024. Epub 2016 Mar 25.
3
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
JAMA. 2014 Jun 25;311(24):2490-8. doi: 10.1001/jama.2014.6368.
4
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.
Ann Rheum Dis. 2015 Jun;74(6):1124-31. doi: 10.1136/annrheumdis-2014-205226. Epub 2014 Jun 30.
5
Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1731-9. doi: 10.1002/acr.22339.
6
Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis.
Arthritis Rheumatol. 2014 Feb;66(2):407-17. doi: 10.1002/art.38219.
7
A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
J Rheumatol. 2012 Jun;39(6):1241-7. doi: 10.3899/jrheum.111229. Epub 2012 Apr 1.
8
The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.
J Rheumatol. 2011 Jul;38(7):1480-6. doi: 10.3899/jrheum.110276.
9
Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma.
Ann Rheum Dis. 2011 Jan;70(1):104-9. doi: 10.1136/ard.2009.127621. Epub 2010 Aug 2.
10
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.
Arthritis Rheum. 2008 May 15;59(5):699-705. doi: 10.1002/art.23564.
Zotero 插件